Valby, Denmark, 16 June 2014 - H. Lundbeck A/S (Lundbeck) today announced results from the CONNECT study showing that Brintellix (vortioxetine) 10 mg/day to 20 mg/day in adults with major depressive disorder (MDD) met the primary study endpoint of demonstrating superiority versus placebo in cognitive function as measured by the Digit Symbol Substitution Test (DSST). These findings will be presented as a late-breaking poster at the 29th International College of Neuropsychopharmacology (CINP) World Congress in Vancouver, Canada on 24 June 2014[i].
Help employers find you! Check out all the jobs and post your resume.
